Physician

Ronald L Drengler, M.D.

According to 2025 Medicare claims, Ronald Drengler, M.D. (NPI: 1265459168) practices medical oncology in the San Antonio-New Braunfels, TX market, with the plurality of this provider's patient population coming from Bexar, TX. This provider's primary affiliated billing organization is SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC (NPI: 1770664542; TIN: 742915297) and primary practice location at 78229-3307.

Drengler's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 355 traditional Medicare patients, billed 371,657 HCPCS/CPT codes, and received $8,321,894 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,574 prescription claims across 206 beneficiaries totaling $3,931,831 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 41 claims. Open Payments data shows 95 records totaling $2,829. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $3,344,831 to $8,321,894. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,098,447 to $3,931,831. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	319	205,328	$3,344,831
2016	329	270,202	$4,473,711
2017	334	233,770	$2,963,244
2018	335	163,733	$2,887,996
2019	339	232,179	$4,366,933
2020	339	211,892	$4,514,100
2021	359	215,939	$4,584,905
2022	337	238,641	$5,933,150
2023	341	308,115	$6,554,800
2024	355	371,657	$8,321,894

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	118	1,004	$1,098,447
2016	133	1,013	$1,488,446
2017	142	1,201	$1,369,118
2018	140	1,145	$2,001,580
2019	155	1,126	$2,700,327
2020	159	1,255	$3,603,760
2021	175	1,364	$3,697,914
2022	189	1,507	$3,242,275
2023	200	1,632	$2,973,601
2024	206	1,574	$3,931,831

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	65	291	$92,041
2016	41	195	$49,365
2017	26	85	$24,396
2018	N/R	75	$11,288
2019	N/R	69	$8,459
2020	N/R	38	$3,335
2021	N/R	11	$1,554
2022	N/R	45	$1,532
2023	24	45	$10,450
2024	N/R	41	$957

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	238	698	$96
80053	Blood test, comprehensive group of blood chemicals	251	1,301	$10
36415	Insertion of needle into vein for collection of blood sample	276	1,069	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	243	1,149	$8
83615	Lactate dehydrogenase (enzyme) level	269	1,424	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	34	1,014	$798,504
Tagrisso	Osimertinib Mesylate	30	900	$493,834
Mekinist	Trametinib Dimethyl Sulfoxide	15	570	$293,521
Nubeqa	Darolutamide	22	630	$271,250
Tafinlar	Dabrafenib Mesylate	19	570	$270,195

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$543
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	22	$414

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	95	$2,829	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ronald L. Drengler, M.D.?

Tedicare shows public-source Medicare data for Ronald L. Drengler, M.D. (NPI 1265459168), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ronald L. Drengler, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ronald L. Drengler, M.D.?

Ronald L. Drengler, M.D. is linked to SOUTH TEXAS ONCOLOGY AND HEMATOLOGY, PLLC (billing NPI 1770664542) in the available physician profile data.

Does Ronald L. Drengler, M.D. have Open Payments data?

Ronald L. Drengler, M.D. has 95 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.